At Delta Hat we are health economists and statisticians who provide support to the pharmaceutical industry. We focus on the technical aspects of evidence based medicine and health technology appraisal – from meta-analysis to cost-effectiveness modelling, and everything in between.
The name of the company represents what we offer - in statistics Greek letters are commonly used to denote unknown parameters. The letter delta is commonly used to represent the difference. Placing a circumflex, ^, or ‘hat’ over a letter denotes the estimator of this value. Delta hat therefore means ‘estimated difference’.
Often in comparative effectiveness and health technology assessment this is the parameter we are trying to estimate – the added value of the new intervention. As the true value can never be observed (at best we conduct a trial to estimate this) further work is often needed to make robust estimates of the benefit of treatment.
Here at Delta Hat, we have the skills to perform such analyses (even our website is built in R), with the experience to help understand the implications of the findings. Please get in touch, as we are more than happy to talk through what solutions we might recommend for any given problem.
We focus exclusively on the technical aspects of evidence based medicine. Our specialisms are in uncontrolled studies/observational data, and survival modelling.
Past projects include matching adjusted indirect comparisons, propensity scoring, advanced survival extrapolations, utility mappings, health economic modelling, teaching, and submission of evidence dossiers to health technology assessment agencies.
We are happy to discuss the kind of projects we are able to offer, and also willing to work in partnership with other vendors.
Our experience covers many areas of health technology assessment and statistical analysis. Below are selected publications which demonstrate particular areas of expertise:
Hatswell AJ, Baio G, Irs A, Berlin J, Freemantle N (2016). The regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999 – 2014. BMJ Open Link
Hatswell AJ, Porter J, Hertel N, Lee D, Latimer NR (2016). The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight. Value in Health Volume 19, Issue 8, Pages 1055-1058 Link
Hatswell AJ, Pennington B, Pericleous L, Rowen D, Lebmeier M, Lee D (2014). Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health and Quality of Life Outcomes Volume 12 Pages 140-149 Link
Bullement A, Underhill S, Fouregay R, Hatswell AJ (2017). Cost effectiveness of previously treated metastatic colorectal cancer in England and Wales. Clinical Colorectal Cancer accepted for publication. Link
Zuckerman JN, Batty AJ, Jones ME (2009) Effectiveness of malaria chemoprophylaxis against Plasmodium falciparum infection in UK travellers: Retrospective observational data. Travel Medicine and Infectious Disease. Volume 7 Issue 6 pages 329-336 Link
Please get in touch if you wish to discuss these areas (or other topics) further.
A number of our projects have led to companion files which are freely downloadable – these are hosted below.